scioCD - Cell surface marker and Cytokine profiling

 

Characterise a certain cell type?

 

Cell composition in a certain tissue sample?

 

In-depth profiling of CD-marker expression?

 

Increase your throughput at high sensitivity levels?

You aim at high reproducibility?

 

 

Our scioCD profiling service covers 206 different proteins :

All these proteins can be analysed in parallel within a single experiment from minute sample amounts. Thereby, scioCD antibody array analysis service is ideally suited to investigate cell composition of tissues or the differentiation status of cultured cells in a highly parallel, fast and robust fashion. In addition, protein distribution in blood samples (plasma / serum) can be analysed efficiently, providing insights in the blood cell composition.

scioCD is a complete sample-to-result service for a variety of different sample types. The respective protocols were developed over a period of 15 years and are optimised towards highest possible sensitivity combined with high reproducibility (coefficients of variation below 10%).

 

 

Target
proteins
      Analysis
Service
      Sample
Types
      Product
brochure
      Contact
us

 

 

 

 

Applications

  • profiling of cell differentiation status
  • stem cell differentiation 
  • investigate soluble CD-molecules for e.g. allograft rejection
  • inflammatory response profiling
  • immuno-oncology profiling of check-point inhibitor targets
  • characterisation of tissue-isolated primary cells
  • immune-cell surface marker profiling on
    • various B-cells 
    • stimulated T-cells
    • patient derived T-cells
    • patient derived dendritic cells
  • oncology profiling for new biomarkers e.g. Leukemia
  • tumor micro-environment profiling
  • profile response to stimuli of cell lines
  • evaluate protein expression changes in silencing/overexpression  experiments
 

Advantages

  • high content - 206 proteins are analysed
  • broad coverage and parallel analysis of
    • CD molecules 
    • cytokines and chemokines
    • other relevant molecules (HLAs, p53)
  • minimal sample requirements
  • native matrixes ( non-fractionated / non-depleted )
  • sensitivity as ELISA or better
  • fully immuno-based assay
  • reliable dual-colour study design
  • high reproducibility, CV < 10%
  • most proteins are covered redundantly by two or more antibodies
  • each antibody is presented in four replicates
  • antibodies are available for follow-up studies

 

 

Target list (version 1) for the scioCD protein profiling service.

Extented version 2 to follow soon ! Contact us for the updated target overview via eMail This email address is being protected from spambots. You need JavaScript enabled to view it.

 

CD Marker Gene name   CD Marker Gene name     Chemokine / Cytokine Gene name     Additional proteins Gene name
CD1a LEU6   CD50 ICAM3     GM-CSF CSF2     ANCA PRTN3
CD2 SRBC   CD52 HE5     IFN alpha IFNA1     BDNF BDNF
CD3 T3G   CD53 TSPAN25     IFN gamma IFNG     Cox1 PTGS1
CD4 LEU3   CD54 ICAM1     IL-1alpha IL1A     CYTL CYTL1
CD5 LEU1   CD55 DAF     IL-1beta IL1B     IgE FCER1A
CD6 TP120   CD56 NCAM1     IL-2 IL2     HLA I  
CD7 LEU9   CD57 B3GAT1     IL-4 IL4     HLA-ABC  
CD8 MAL   CD58 LFA3     IL-6 IL6     HLA-DP HLA-DPB1
CD9 MIC3   CD59 MIC11     IL-7 IL7     HLA-DQ  
CD10 MME   CD61 ITGB3     IL-8 CXCL8     HLA-DR  
CD11a ITGAL   CD62L SELL     IL-10 IL10     MPO MPO
CD11b ITGAM   CD62p SELP     IL-12B IL12B     NT-4 NTF4
CD11c ITGAX   CD63 TSPAN30     IL-13 IL13     NTAL LAT2
CD13 ANPEP   CD66a CEACAM1     IL-15 IL15     pan HLA-class II  
CD14     CD66b CEACAM8     IL-16 IL16     p53 TP53
CD15 FUT4   CD66c CEACAM6     IL-18 IL18     p72Syk SYK
CD16 FCGR3A   CD66d CEACAM3     IL-37 IL37     TRYG1 TPSG1
CD17     CD66e CEACAM5     LIF LIF     TSLPR CRLF2
CD18 ITGB2   CD69 CLEC2C     TNF alpha TNF     tTG TGM2
CD19 LEU12   CD70 TNFSF7     TSLP TSLP     VEGF VEGFA
CD20 MS4A1   CD71 TFRC                
CD21 CR2   CD72 Lyb-2     Eotaxin-1 CCL11        
CD22 SIGLEC2   CD79a MB1     MIP-1 alpha CCL3        
CD23 FCER2   CD80 LAB7     RANTES CCL5        
CD24     CD86 LAB72     MCP-2 CCL8        
CD25 IL2RA   CD95 FAS     MCP-3 CCL7        
CD27 TNFRSF7   CD97       MIP-4 CCL18        
CD28 TP44   CD98 SLC3A2                
CD29 ITGB1   CD99 MIC2                
CD30 TNFRSF8   CD105 ENG                
CD31 PECAM1   CD106 VCAM1                
CD33 SIGLEC3   CD116 CSF2RA                
CD34     CD117 KIT                
CD35 CR1   CD123 IL3RA                
CD36 GP3B   CD131 CSF2RB                
CD37 TSPAN26   CD137 TNFRSF9                
CD38 ADPRC 1   CD139                  
CD40 TNFRSF5   CD147 BSG                
CD41 ITGA2B   CD162 SELPLG                
CD42b GP1BA   CD177 NB1                
CD43 SPN   CD222 IGF2R                
CD44 MDU2   CD223 LAG3                
CD45 PTPRC   CD230 PRNP                
CD46 MCP   CD235a GYPA                
CD47 MER6   CD235b GYPB                
CD48 BCM1   CD253 TNFSF10                
CD49d ITGA4   CD274 PDL1                
      CD279 PD1                

 

Which sample types can be analysed ?

Within our scioCD analysis service the following samples can be analysed:

  • plasma / serum
  • fresh frozen tissue samples
  • cellular content
  • cell culture supernatant
  • cerebrospinal fluid
  • additional sample types on request

  

Sample-to-result service

Within the analysis service, we will not only carry out the microarray experiments but also support you with a suggestion for an appropriate microarray study design as well as with the sample selection process in order to address your scientific question in the optimal way. Within 3-4 weeks after receipt of your samples you will receive a customised study report including a statistical analysis.

Our analysis service includes:

  • definition of an appropriate study design
  • sample preparation
  • protein extraction
  • protein concentration measurements
  • protein quality control
  • sample labelling
  • sample purification
  • incubation of the samples on antibody microarrays
  • microarray scanning
  • raw data acquisition
  • data normalisation
  • data analysis including cluster analysis
  • statistical testing for differentially abundant proteins
  • comprehensive study report

 

 

Do you like to subscribe our newsletter ?      Yes   No

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status

scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation. Features 1030 highly relevant proteins are profiled in a single assay Phosphorylation status combined with protein expression levels Tyrosine,…
Read more
scioDiscover - Protein Profiling on expression level

scioDiscover - Protein Profiling on expression level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…
scioCD - Cell surface marker and Cytokine profiling

scioCD - Cell surface marker and Cytokine profiling

  Characterise a certain cell type?   Cell composition in a certain tissue sample?   In-depth profiling of CD-marker expression?   Increase your throughput at high sensitivity levels? You aim…
scioUbi

scioUbi

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse up to 1,000 proteins in a single assay.   Features Ubiquitination…
scioCyto

scioCyto

Cytokine profiling scioCyto is a high-content analysis service for cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or cell cultur supernatants…

News

New article | Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer

| Jan 2019 | In the article, scientists at Tel Aviv University used our scioDiscover platform to analyse tumor-associated eosinophils in colorectal cancer. The full article is published in Cancer Immunology Research.

 

New article | Macrophage-derived IL-1β and TNF-α regulate arginine metabolism in neuroblastoma

| Decembre 2018 | Study by our collaborator Dr Francis Mussai at University of Birmingham suggests arginine metabolism as a target for neuroblastoma therapy. At Sciomics we are proud of having contributed to this exciting study by a scioDiscover protein profiling study. The article is published in Cancer Research.

 

New article | Protection from ischemia reperfusion injury-induced inflammation and fibrosis in C5aR2-deficient mice

| June 2018 | Complement component 5a receptor 2 (C5AR2) deficient mice are protected from inflammation and fibrosis in response to ischemia reperfusion injury. Our scioPhospho platform supported scientists at the Medical School Hannover to elucidate the underlying mechanism. The data were recently published in Kidney International.

 

New article | Modeling Congenital Adrenal Hyperplasia and Testing Interventions for Adrenal Insufficiency Using Donor-Specific Reprogrammed Cells

| January 2018 | A scioDiscover protein microarray study contributed to an article in Cell Reports. In this study Gerard Ruiz-Babot et al. analysed a donor specific reprogramming of cells.

Customer testimonial Leonardo Guasti, PhD (senior author):

This has undoubtedly opened new avenues in our research. We have found the Sciomics team to be extremely helpful and efficient during the whole process, from advising the best strategy to the final interpretation of results.

> More testimonials

A glas full of hope | Ein Glas Hoffnung

| January 2018 | Article on the StartUp Sciomics and our antibody microarray platform by our partner SCHOTT nexterion.

> English version "A glass full of hope"

> Deutsche Version "Ein Glas Hoffnung"

Tweets

  • 4 days ago

    RT @MCDS_Therapy: Fantastic news - we are now halfway to reaching our recruitment target in the UK! 🙌 Recruitment will continue at our two…

  • 7 days ago

    RT @MCDS_Therapy: Huge congratulations to the @AKUSociety on the positive outcomes of their #DrugRepurposing clinical trial 👏 We are using…

  • 10 days ago

    RT @MCDS_Therapy: Recruitment into our #ClinicalTrial is coming along nicely and we have now got 5 participants registered in the UK! 🙌 R…

  • 13 days ago

    RT @BioRNCluster: 🗣️#BioRNMember @sciomics has two open positions: one lab technician and one team assistant. Spread the word! Sciomics - E…

  • 23 days ago

    RT @MCDS_Therapy: #DrugRepurposing is significantly faster and cheaper than conventional drug discovery. This is why we are using it in our…